Prasugrel 10 mg daily x 2 weeks + Clopidogrel 75 mg daily x 2 weeks
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Systolic Heart Failure
Conditions
Systolic Heart Failure
Trial Timeline
May 15, 2013 → Dec 28, 2015
NCT ID
NCT01765400About Prasugrel 10 mg daily x 2 weeks + Clopidogrel 75 mg daily x 2 weeks
Prasugrel 10 mg daily x 2 weeks + Clopidogrel 75 mg daily x 2 weeks is a approved stage product being developed by Daiichi Sankyo for Systolic Heart Failure. The current trial status is completed. This product is registered under clinical trial identifier NCT01765400. Target conditions include Systolic Heart Failure.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01765400 | Approved | Completed |
Competing Products
8 competing products in Systolic Heart Failure
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| olmesartan medoxomil + hydrochlorothiazide, if necessary + nitrendipine + hydrochlorothiazide, if necessary | Daiichi Sankyo | Phase 3 | 77 |
| IvabRadine hemisulfate Sustained-release Tablets + placebo | Jiangsu Hengrui Medicine | Phase 2/3 | 65 |
| LCZ696 + Valsartan + AHU377 + Placebo | Novartis | Phase 2 | 52 |
| valsartan, amlodipine, HCTZ + Losartan, HCTZ followed by valsartan, amlodipine, HCTZ | Novartis | Approved | 85 |
| Sacubitril/Valsartan | Novartis | Pre-clinical | 23 |
| Finerenone (Kerendia, BAY94-8862) | Bayer | Phase 3 | 74 |
| Finerenone (Kerendia, BAY94-8862) + Placebo | Bayer | Phase 3 | 74 |
| 6R-BH4 | BioMarin Pharmaceutical | Phase 2 | 49 |